n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
GAITHERSBURG, Md. , Nov. 14, 2023 /PRNewswire/ — YS Biopharma Co. , Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical corporation committed to discovery, development and manufacturing. and offering next-generation vaccines and therapeutics for infectious diseases and cancer, is pleased to announce that Noble Capital Markets (“Noble”) has announced the company’s capital studies policy with an “out of consistency” rating and a 12-month price target. . $5. 25 consistent with stock. The full report by Gregory Aurand, Senior Healthcare and Medical Device Analyst at Noble Capital Markets, as well as complex news and market insights on YS Biopharma, can be found on Channelchek. The report can also be found online about the company’s investor relations. page here.
Highlights of the project include:
Novel Generation PIKA. La Immunomodulatory Platform PIKA has the ability to target and stimulate the immune response in a wide variety of vaccines and immuno-oncology treatments. PIKA activates and complements the body’s immune reaction, extending the effectiveness of vaccines. In oncology, with its modes of action capable of inducing the production of tumor-inhibiting cytokines and mobile tumor apoptosis, PIKA can be implemented for broad-spectrum antitumor activity in cancers.
Significant opportunities in the antivirals and immuno-oncology markets. There are significant unmet desires in Africa, South-East Asia and China, among other parts of the world, for rabies, hepatitis B and cancer control. The Asia-Pacific region is expected to witness the rate of expansion in the world, with higher degrees of immunotherapy use, due to low vaccine penetration, increasing cancer prevalence, and increased knowledge of patients and disposable income.
Commercialized rabies vaccine. YS Biopharma is currently marketing the YSJA rabies virus vaccine, the first aluminum-free lyophilized rabies vaccine introduced in China. The YSJA vaccine, a more classic vaccine, is more effective and has a higher protection profile than other vaccines and has achieved approximately 11% market share since its launch in 2020, the pandemic in calendar year 2023 had a negative effect on the origin chain and production performance. The YSJA vaccine is not only helping to improve the structure of the advertising infrastructure, but it is also helping the studies and progression process of PIKA. .
Start with superior performance. Noble’s one-year value target of $5. 25 is based on a FY 2029 earnings per share (EPS) of RMB 6. 93 ($0. 95), reduced to 30% and applying a Nasdaq earnings multiple of 20x. The multiple reflects an average value-to-earnings ratio of the Nasdaq that Noble believes reflects the opportunity for growth. For a small business with less secure money and progression and product risks, Noble assigns a higher drawdown rate.
All reports on YS Biopharma prepared through analysts constitute reviews of such analysts and are not necessarily those of the Company. YS Biopharma is not to blame for the content, accuracy, or timelines provided through analysts. YS Biopharma does not warrant or assume, expressly or implied, any legal duty for the accuracy, completeness, or usefulness of any information, assumptions, data, forecasts, value targets, estimates, or projections contained in industry reports or notes provided through analysts, and the dissemination of such industry reports or notes does not necessarily constitute or mean endorsement or advice through YS Biopharma. The Company participates in the Company-Sponsored Research Program (“CSRP”) of Noble Capital Markets and Noble Capital Markets receives reimbursement from the Company for such participation. No component of SRFC compensation was, is, or will be directly or similar to any express advice or review expressed through the analyst in this study report.
About YS BiopharmaYS Biopharma is a global biopharmaceutical corporation committed to the discovery, development, production, and delivery of next-generation vaccines and curative biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulator generation platform and a new generation of preventive drugs and curative biologics targeting rabies, coronavirus, hepatitis B, influenza, shingles, and other viral infections. YS Biopharma has operations in China, the United States, Singapore and the Philippines, and is led through a control team that combines rich local expertise and global delight in the biopharmaceutical industry. For more information, visit www. investor. ysbiopharm. com.
About Noble Capital MarketsNoble Capital Markets, Inc. , incorporated in 1984 as a full-service SEC/FINRA registered broker-dealer, committed exclusively to serving small and small-cap corporations with little following through investment banking, wealth management, trading and execution, and equity studies. Over the more than 37 years, Noble has raised billions of dollars for those corporations and published more than 45,000 equity study reports. For more information, visit www. noblecapitalmarkets. com or email contact@noblecapitalmarkets. com.
About ChannelchekChannelchek (. com) is a comprehensive investor-centric portal, showcasing more than 6,000 emerging expanding corporations, providing complex market data, independent research, balanced news, video webcasts, exclusive interviews with senior executives and virtual roadshows. Available to the public at all levels with no fee or obligation. The investigation into Channelchek is conducted through Noble Capital Markets, Inc. , an SEC/FINRA registered broker since 1984. For more information, visit www. channelchek. com or email contacto@channelchek. com.
Cautionary Note Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. amended, and the Private Act Securities Litigation Reform Act of 1995. All statements other than statements of past or existing fact included in this press release are forward-looking statements, including, without limitation, statements regarding expected expansion of YS Biopharma, the progress of all product candidates, the progress and effects of all clinical trials, the ability of YS Biopharma to source and retain talent and the monetary position of YS Biopharma following the closing of the business combination. Forward-looking statements can be understood by the use of words such as “estimate”, “plan”, “project”, “forecast”, “intend”, “intend”, “expect”, “anticipate”, “believe”. “seek”, “target” or other similar expressions that expect or imply long-term events or trends or that are not statements of long-standing matters. These statements are based on assumptions, whether known in this press release, and on YS’s existing expectations. Biopharma control and are not actual performance expectations.
These involve dangers, uncertainties and other points that would possibly cause actual effects, degrees of activity, functionality or achievements to differ materially from those expressed or implied by such forward-looking announcements. Although YS Biopharma believes it has a moderate basis for each forward-looking view contained in this press release, YS Biopharma cautions that those announcements are based on a combination of recently known facts and points and long-term projections, which are inherently uncertain. In addition, there are dangers and uncertainties that are described in the latest release. prospectus related to the proposed business combination and in other documents filed through YS Biopharma from time to time with the SEC. These documents would possibly identify and address other vital hazards and uncertainties that may also cause actual events and effects to differ materially from those contained in the document.
YS Biopharma cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. These forward-looking statements are subject to a number of threats and uncertainties, including, among others, the ability to recognize the expected benefits of the business combination, the prices associated with the transaction, the effect of the global COVID pandemic. -19, the threat that the transaction will disrupt existing plans and operations due to the consummation of the transaction, the final results of any potential litigation, any governmental or regulatory proceedings, the advertising functionality of the announced vaccine product and the effects of progression from the YS clinical trial. Biopharma’s product candidates, as well as other threats and uncertainties, including those included in YS Biopharma’s filings with the SEC. There may be other threats that YS Biopharma is not aware of or that YS Biopharma considers irrelevant, which could also cause actual effects to differ from those contained in the forward-looking statements. In light of the significant uncertainties related to such forward-looking statements, nothing in this press release should be construed as a representation by any user that the forward-looking statements set forth herein will become known or that any of the weighted effects of such Forward-looking statements: attractive statements will result. The forward-looking statements contained in this press release constitute YS Biopharma’s views as of the date of this press release. Subsequent events and progressions would likely supersede those perspectives. However, although YS Biopharma may update such forward-looking statements in the future, there is no intention to do so unless required by applicable law. Therefore, you should not rely on such forward-looking statements as constituting YS Biopharma’s views as of any date subsequent to the date of this press release. Except as required by law, YS Biopharma undertakes no legal responsibility to update such forward-looking statements.
Investor Relations ContactsAlyssa LiDirector of Investor RelationsEmail: ir@yishengbio. com
Robin YangPartner, ICR, LLCTel: 1 (212) 537-4035Email: YSBiopharma. IR@icrinc. com
View the content to download the multimedia: https://www. prnewswire. com/apac/news-releases/noble-capital-markets-initiates-coverage-on-ys-biopharma-with-outperform-rating-and-us5- 25 -target-price-301987544. html
SOURCE YS Biopharma Co. , Ltd.